Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

Matthews, HASAN; Paldanius, Paivi; Proot, Pieter; Chiang, YannTong; Stumvoll, Michael; Del Prato, Stefano

doi:10.1016/s0140-6736(19)32131-2

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

Matthews D. R., Paldanius P. M., Proot P., Chiang Y., Stumvoll M., Del Prato S.

LANCET, cilt.394, sa.10208, ss.1519-1529, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 394 Sayı: 10208
Basım Tarihi: 2019
Doi Numarası: 10.1016/s0140-6736(19)32131-2
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1519-1529
İstanbul Üniversitesi Adresli: Evet

Özet

Background Early treatment intensification leading to sustained good glycaemic control is essential to delay diabetic complications. Although initial combination therapy has been suggested to offer more opportunities than a traditional stepwise approach, its validity remains to be determined.